文献速递妇科

晚期卵巢癌新辅助化疗后手术方式与生存分析

Survival and Surgical Approach among Women with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy.
PubMed 文献 · J Minim Invasive Gynecol · 2021-10-11

本研究利用美国国家癌症数据库纳入2010至2016年诊断为IIIC/IV期上皮性卵巢癌、确诊90天内接受新辅助化疗并随后行间隔减瘤术的8085例女性,比较微创与开腹手术的总体生存。微创间隔减瘤术比例从2010年2%升至2016年11%,微创与开腹组中位OS分别为36.5与35.2个月(HR 0.94,95%CI 0.86-1.04),校正后仍无差异(HR 0.95,95%CI 0.86-1.04)。

要点

  • 新辅助化疗后微创间隔减瘤术比例由2010年2%升至2016年11%,呈近6倍增长。
  • 微创与开腹间隔减瘤术OS无差异(中位36.5 vs 35.2个月,HR 0.94,95%CI 0.86-1.04)。
  • 微创组住院3天、开腹组5天(p<.01),术后再入院无差异。

核心结论

  • 对新辅助化疗后的晚期上皮性卵巢癌女性,微创间隔减瘤术与开腹手术的总体生存相似。

研究设计与样本

  • 基于美国国家癌症数据库的回顾性队列研究,纳入2010至2016年诊断为IIIC/IV期上皮性卵巢癌、确诊90天内接受新辅助化疗并随后行间隔减瘤术的女性,共8085例。
  • 主要暴露为间隔减瘤术路径(微创 vs 开腹),按意向治疗分析;主要结局为总体生存(OS)。

主要发现

  • 6713例(83%)行开腹间隔减瘤术,1372例(17%)行微创间隔减瘤术。
  • 微创间隔减瘤术比例从2010年2%升至2016年11%,呈近6倍增长。
  • 微创与开腹组中位OS分别为36.5与35.2个月(HR 0.94,95%CI 0.86-1.04),校正人口学与临床变量后仍无差异(HR 0.95,95%CI 0.86-1.04)。
  • 年龄较大(OR 1.35,95%CI 1.05-1.74)与西班牙裔(OR 1.46,95%CI 1.14-1.88)女性接受微创间隔减瘤术的 odds 增加,低收入的女性(<$38000/year)odds 降低(OR 0.76,95%CI 0.60-0.97,p = .03)。
  • 微创与开腹组住院时间分别为3天与5天(p <.01),术后再入院需求无差异。

临床怎么用

  • 对经新辅助化疗后适合间隔减瘤术的晚期上皮性卵巢癌女性,微创路径可作为与开腹生存相当的选项,并可能缩短住院时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: To evaluate the effect of surgical approach on overall survival (OS) for women with advanced, epithelial ovarian cancer (EOC) after neoadjuvant chemotherapy (NACT) and determine the sociodemographic and clinical factors associated with surgical approach. DESIGN: The primary exposure was surgical approach to interval cytoreduction, minimally invasive versus open, and was evaluated by intention to treat. Primary outcome was OS. Associations were examined using Chi-squared tests, Wilcoxon rank sum tests, and multivariate logistic regression. Survival analysis was performed with Kaplan-Meier methods and Cox proportional hazards. SETTING: The National Cander Database was used to identify eligible patients. PATIENTS: Women diagnosed with stage IIIC/IV EOC from 2010-2016. INTERVENTIONS: Patients were included if they were treated with NACT within 90 days of diagnosis before interval cytoreductive surgery (CRS). MEASUREMENTS AND MAIN RESULTS: A total of 8085 women were identified; 6713 (83%) underwent open interval CRS, and 1372 (17%) underwent minimally invasive interval CRS. The proportion undergoing minimally invasive CRS after NACT increased from 2% in 2010 to 11% in 2016, a nearly 6-fold increase. There was no difference in OS between women who underwent minimally invasive and open interval CRS (median OS 36.5 vs 35.2 months, HR 0.94, 95% CI, 0.86-1.04). After adjusting for demographic and clinical variables, including age, race, ethnicity, income, and Charlson/Deyo score, no difference in OS was observed (HR 0.95, 95% CI, 0.86-1.04). Women of older age (OR 1.35, 95% CI, 1.05-1.74) and Hispanic ethnicity (OR 1.46, 95% CI, 1.14-1.88) had increased odds of receiving minimally invasive CRS after NACT, whereas low income (<$38000/year) women had decreased odds (OR 0.76, 95% CI, 0.60-0.97, p = .03). Length of stay differed for patients undergoing minimally invasive versus open interval CRS (3 vs 5 days, p <.01), but there was no difference in need for postoperative readmission. CONCLUSIONS: Minimally invasive CRS has similar survival outcomes to open CRS among women with EOC who have undergone NACT.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Persenaire C, Pyrzak A, Barber EL, et al. Survival and Surgical Approach among Women with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy. J Minim Invasive Gynecol. 2021. PMID: 34648931. doi:10.1016/j.jmig.2021.09.716

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。